CLINICAL_TRIALS
trial_result
· 2013-01-31
Clinical Trial Update: Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease [Phase 2]
Summary
A Phase 2 trial comparing three dosage levels of SAM-531 in outpatients with mild-to-moderate Alzheimer disease was terminated, with results posted in 2013.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Alzheimer Disease | Phase 2 | Status: TERMINATED | Results posted: 2013-01-31